Alx Oncology Shares Down in Pre-market as Jefferies Downgrades Stock to 'Hold'
Jefferies Downgrades ALX Oncology Holdings to Hold, Lowers Price Target to $2
Express News | ALX Oncology Holdings Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $2 From $12
Express News | Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdingsto Overweight
ALX Oncology to Present Updated Results From Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients With HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
ALX Oncology Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
